About this Research Topic
CLE (Cutaneous Lupus Erythematosus) is an autoimmune disease that can occur with or without systemic manifestations; people with CLE may experience symptoms including photosensitivity, rash, pain, and pruritis as well as skin damage that may worsen over time and can include disfiguring and irreversible scarring alopecia and skin dyspigmentation.
Patients with CLE may frequently suffer from comorbidities as depression and cardiovascular disease as well as functional, mental, and emotional HRQoL (health-related quality of life) impairment associated with substantial healthcare expenditures.
Currently no targeted therapies are approved for CLE and effective treatments are needed to address the unmet needs of these patients.
There is a need to increase awareness of what is CLE as well as its pathophysiology and impact on patient quality of life and this Research Topic would help address this ensuring a larger audience has access to this relevant information.
This Research Topic aims to elaborate up to 9 review articles approaching in further detail key elements of CLE (cutaneous lupus erythematosus) disease, and its impact in clinical practice and patients. Detailed sub-topics as below:
1-Clinical aspects of CLE
• Epidemiology
• Subtype description/presentation
• Underrepresented patient population
• Unmet needs
2- Burden of Disease
• Patient journey/delayed diagnosis
• Co-morbidities, including psychological aspects
• PTSD (fear of disease returning)
3- Interface between CLE and SLE
• Organ involvement in CLE and SLE: similarities and differences
• Is CLE a different entity or not?
4- Pathogenesis/pathophysiology- Part 1
• Genetic learnings from CLE and SLE
• Environmental factors including sunlight, smoking, vitamin D, viral, drugs
5 - Pathogenesis/pathophysiology – Part 2
• Histopathology/cellular description of CLE (pathologist)
• Role of pDCs and other cell types
• CLE subtypes (focus on pathophysiology)
6 - CLE disease assessment in clinical trials; Outcome measures and utility as endpoints in clinical trials and practice:
• Outcome measures and utility of endpoints in clinical trials
• Assessments used in clinical practice
• Current and future endpoints, clinical meaningfulness
• Patient-reported outcomes (PROs)/Health-related quality of Life (HRQoL) measures
7 - Management of CLE in clinical practice
• Current treatment approaches and guidelines
8 - Emerging therapies
• Review new/recent studies; what is working and what not working
9 - Health equity in CLE
• Underrepresented/Underserved patient populations
• Explore different geographies (ex-US)
• Gender
Topic Editor N.F. is an employer of Biogen and holds shares of Biogen and OMass Therapeutics. Topic Editor V.W. receives grants from grant/research support from Biogen, Celgene, Gilead, Janssen, and Viela. The other Topic Editors declares no competing interest in regard to the Research Topic subject.
Patients with CLE may frequently suffer from comorbidities as depression and cardiovascular disease as well as functional, mental, and emotional HRQoL (health-related quality of life) impairment associated with substantial healthcare expenditures.
Currently no targeted therapies are approved for CLE and effective treatments are needed to address the unmet needs of these patients.
There is a need to increase awareness of what is CLE as well as its pathophysiology and impact on patient quality of life and this Research Topic would help address this ensuring a larger audience has access to this relevant information.
This Research Topic aims to elaborate up to 9 review articles approaching in further detail key elements of CLE (cutaneous lupus erythematosus) disease, and its impact in clinical practice and patients. Detailed sub-topics as below:
1-Clinical aspects of CLE
• Epidemiology
• Subtype description/presentation
• Underrepresented patient population
• Unmet needs
2- Burden of Disease
• Patient journey/delayed diagnosis
• Co-morbidities, including psychological aspects
• PTSD (fear of disease returning)
3- Interface between CLE and SLE
• Organ involvement in CLE and SLE: similarities and differences
• Is CLE a different entity or not?
4- Pathogenesis/pathophysiology- Part 1
• Genetic learnings from CLE and SLE
• Environmental factors including sunlight, smoking, vitamin D, viral, drugs
5 - Pathogenesis/pathophysiology – Part 2
• Histopathology/cellular description of CLE (pathologist)
• Role of pDCs and other cell types
• CLE subtypes (focus on pathophysiology)
6 - CLE disease assessment in clinical trials; Outcome measures and utility as endpoints in clinical trials and practice:
• Outcome measures and utility of endpoints in clinical trials
• Assessments used in clinical practice
• Current and future endpoints, clinical meaningfulness
• Patient-reported outcomes (PROs)/Health-related quality of Life (HRQoL) measures
7 - Management of CLE in clinical practice
• Current treatment approaches and guidelines
8 - Emerging therapies
• Review new/recent studies; what is working and what not working
9 - Health equity in CLE
• Underrepresented/Underserved patient populations
• Explore different geographies (ex-US)
• Gender
Topic Editor N.F. is an employer of Biogen and holds shares of Biogen and OMass Therapeutics. Topic Editor V.W. receives grants from grant/research support from Biogen, Celgene, Gilead, Janssen, and Viela. The other Topic Editors declares no competing interest in regard to the Research Topic subject.
Keywords: Cutaneous Lupus Erythematosus, skin disease, skin symptoms, skin damage, CLE
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
